TNSN04045A1 - Compositions de valdecoxib a delitement intra-oral - Google Patents

Compositions de valdecoxib a delitement intra-oral

Info

Publication number
TNSN04045A1
TNSN04045A1 TNP2004000045A TNSN04045A TNSN04045A1 TN SN04045 A1 TNSN04045 A1 TN SN04045A1 TN P2004000045 A TNP2004000045 A TN P2004000045A TN SN04045 A TNSN04045 A TN SN04045A TN SN04045 A1 TNSN04045 A1 TN SN04045A1
Authority
TN
Tunisia
Prior art keywords
compositions
intraoral delivery
valdecoxib
valdecoxib compositions
delivery
Prior art date
Application number
TNP2004000045A
Other languages
English (en)
Inventor
Trang T Le
Blake C Ludwig
Joseph P Reo
Uday J Shah
Ken Yamamoto
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of TNSN04045A1 publication Critical patent/TNSN04045A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DES COMPRIMES DE VALDECOXIB A DELITEMENT ORAL; FONDANT RAPIDEMENT; ET DES PROCEDES POUR LA PREPARATION DE CES FORMES POSOLOGIQUES SONT PROPOSES. LES COMPOSITIONS SONT UTILES DANS LE TRAITEMENT OU LA PROPHYLAXIE DE TROUBLES ET D'AFFECTIONS A MEDIATION PAR LA CYCLO-OXYGENASE - 2.
TNP2004000045A 2001-09-26 2004-03-23 Compositions de valdecoxib a delitement intra-oral TNSN04045A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26
PCT/US2002/030161 WO2003026623A1 (fr) 2001-09-26 2002-09-23 Compositions de valdecoxib se désintégrant dans la bouche

Publications (1)

Publication Number Publication Date
TNSN04045A1 true TNSN04045A1 (fr) 2006-06-01

Family

ID=23267542

Family Applications (2)

Application Number Title Priority Date Filing Date
TNP2004000045A TNSN04045A1 (fr) 2001-09-26 2004-03-23 Compositions de valdecoxib a delitement intra-oral
TNP2004000047A TNSN04047A1 (fr) 2001-09-26 2004-03-24 Compositions a delitement intra-oral, acceptables du point de vue organoleptique.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TNP2004000047A TNSN04047A1 (fr) 2001-09-26 2004-03-24 Compositions a delitement intra-oral, acceptables du point de vue organoleptique.

Country Status (25)

Country Link
US (1) US20030181501A1 (fr)
EP (2) EP1490035A1 (fr)
JP (2) JP2005512964A (fr)
KR (2) KR20040044990A (fr)
CN (2) CN1633281A (fr)
AP (2) AP2004002999A0 (fr)
AR (1) AR037239A1 (fr)
BR (2) BR0212861A (fr)
CA (2) CA2461044A1 (fr)
CO (2) CO5570684A2 (fr)
EA (2) EA200400352A1 (fr)
EC (1) ECSP045029A (fr)
GE (1) GEP20063856B (fr)
HK (1) HK1079988A1 (fr)
IL (2) IL160855A0 (fr)
IS (2) IS7177A (fr)
MA (2) MA27542A1 (fr)
MX (2) MXPA04002652A (fr)
NO (2) NO20041258L (fr)
OA (2) OA12707A (fr)
PL (2) PL369297A1 (fr)
TN (2) TNSN04045A1 (fr)
WO (2) WO2003026623A1 (fr)
YU (1) YU34804A (fr)
ZA (2) ZA200401953B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (fr) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Compositions pharmaceutiques comprenant un ether et un inhibiteur selectif de la cyclooxygenase-2 et leur utilisations
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
KR20130018956A (ko) * 2004-08-10 2013-02-25 아지노모토 가부시키가이샤 쓴맛이 감소된 나테글리니드 함유 제제
EP1839650A1 (fr) * 2004-12-28 2007-10-03 Eisai R&D Management Co., Ltd. Comprime a desintegration rapide et son procede de fabrication
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
TW200732000A (en) * 2005-12-20 2007-09-01 Eisai R&D Man Co Ltd Orally disintegrating table comprising fat-soluble drug
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20090136570A1 (en) * 2006-01-20 2009-05-28 Bhagwant Rege Taste-Masked Tablets and Granules
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
US20110318412A1 (en) * 2006-05-19 2011-12-29 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
KR101903781B1 (ko) * 2007-06-06 2018-11-13 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
US20100184785A1 (en) * 2007-06-06 2010-07-22 Basf Se Pharmaceutical formulation for the production of chewable tablets and lozenges
EP2170273B1 (fr) * 2007-06-06 2014-11-26 Basf Se Préparation pharmaceutique pour produire des comprimés à délitement rapide
US8568780B2 (en) * 2007-06-06 2013-10-29 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
CA2704929C (fr) * 2007-08-07 2018-05-15 Pamela Palmer Compositions et procedes de sedation et d'analgesie procedurales utilisant les formes posologiques transmucosales orales
US20110086070A1 (en) * 2008-03-24 2011-04-14 Munish Talwar Orally disintegrating compositions of rhein or diacerein
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
KR101753411B1 (ko) * 2008-11-25 2017-07-03 미쓰비시 타나베 파마 코퍼레이션 구강 내 속붕괴성정 및 그의 제조 방법
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
ZA964928B (en) * 1995-06-13 1997-12-10 American Home Prod Oral formulations of S(+)-etodolac.
AU6964396A (en) * 1995-10-20 1997-05-07 Pharmacia & Upjohn Company Blister package
JPH11512754A (ja) * 1996-05-17 1999-11-02 メルク エンド カンパニー インコーポレーテッド シクロオキシゲナーゼ―２媒介疾患の一日一回治療用組成物
EP0863134A1 (fr) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophényle)-3-(4-méthylesulphonylephényle)-2-cyclopentène-1-one comme inhibiteur de la cyclooxygénase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
BR0008059A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Composições de valdecoxib
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
MXPA03001407A (es) * 2000-08-18 2003-06-06 Pharmacia Corp Formulacion oral de desintegracion rapida de un inhibidor de ciclooxigenasa-2.

Also Published As

Publication number Publication date
PL369298A1 (en) 2005-04-18
GEP20063856B (en) 2006-06-26
WO2003026697A2 (fr) 2003-04-03
JP2005506987A (ja) 2005-03-10
IL160848A0 (en) 2004-08-31
IL160855A0 (en) 2004-08-31
BR0212861A (pt) 2004-10-05
WO2003026623A1 (fr) 2003-04-03
ZA200401953B (en) 2005-05-09
MXPA04002652A (es) 2004-06-07
EA200400357A1 (ru) 2004-08-26
CO5570659A2 (es) 2005-10-31
US20030181501A1 (en) 2003-09-25
OA13060A (en) 2006-11-10
CA2461630A1 (fr) 2003-04-03
AR037239A1 (es) 2004-11-03
ECSP045029A (es) 2004-04-28
IS7178A (is) 2004-03-11
EP1429736A2 (fr) 2004-06-23
CN1633281A (zh) 2005-06-29
AP2004002998A0 (en) 2004-03-31
EA200400352A1 (ru) 2004-12-30
MXPA04002798A (es) 2004-07-05
CA2461044A1 (fr) 2003-04-03
WO2003026623A8 (fr) 2004-09-30
CO5570684A2 (es) 2005-10-31
WO2003026697A3 (fr) 2003-07-03
AP2004002999A0 (en) 2004-03-31
KR20040044990A (ko) 2004-05-31
KR20040058189A (ko) 2004-07-03
HK1079988A1 (zh) 2006-04-21
MA27542A1 (fr) 2005-10-03
PL369297A1 (en) 2005-04-18
IS7177A (is) 2004-03-11
MA27682A1 (fr) 2006-01-02
NO20041532L (no) 2004-04-15
BR0212778A (pt) 2004-12-07
TNSN04047A1 (fr) 2006-06-01
ZA200402364B (en) 2005-01-13
EP1490035A1 (fr) 2004-12-29
OA12707A (en) 2006-06-26
CN1703203A (zh) 2005-11-30
NO20041258L (no) 2003-03-27
JP2005512964A (ja) 2005-05-12
YU34804A (sh) 2006-08-17

Similar Documents

Publication Publication Date Title
TNSN04045A1 (fr) Compositions de valdecoxib a delitement intra-oral
Chumbley et al. The effect of indomethacin (an aspirin-like drug) on the rate of orthodontic tooth movement
Samra et al. Tooth supported overdenture: a concept overshadowed but not yet forgotten!
TR200002207T1 (tr) Slekoksib bileşikleri.
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
HUP0204023A2 (hu) Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények
TWI265808B (en) Valdecoxib compositions
DK0831791T3 (da) Transport af lægemiddelstoffer til den nedre gastrointestinalkanal
BR0215133A (pt) Placa mio-relaxante intra-oral e método para sua utilização
FR2727015B1 (fr) Compositions pharmaceutiques liquides a base d'ondansetron
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
RU2009148278A (ru) Применение эстриола в низкой дозе
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
HUP0402178A2 (hu) 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
TNSN96101A1 (fr) Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques
FR2712495B1 (fr) Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant.
MY144781A (en) Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
Upadhyay et al. Fabrication of a functional palatal saliva reservoir by using a resilient liner during processing of a complete denture
TNSN04056A1 (fr) Compositions de valdecoxib a delitement intra-oral preparees par un procede de sechage par pulverisation
TNSN00163A1 (fr) Composition pour la prevention et le traitement des dysfonctions et des maladies renales
WO2002055062A3 (fr) Comprime pharmaceutique comprenant du mesylate de paroxetine
Axéll Treatment of smarting symptoms in the oral mucosa by appliance of lingual acrylic splints
Tangxia et al. Effect of different porcelain-fused-to-metal crown inner metal materials on the level of soluble intercellular adhesion molecule-1 and interleukin-lß in gingival crevicular fluid.